Results 31 to 40 of about 9,259 (230)

Plasma levels of IL-1β and IL-37 in patients with severe haemophilia

Journal of International Medical Research, 2020
Objective Haemophilia A and B are disorders caused by the lack of clotting factors VIII and IX, respectively. Repeated bleeding into the same joint leads to haemophilic arthropathy (HA).
Pei-Chin Lin, Shyh-Shin Chiou, Wan-Yi Hsu, Yu-Mei Liao, Shih-Pien Tsai, Hsiu-Lan Su, Ping-Tao Lu, Yu-Hsin Tseng   +7 more
doaj   +1 more source

Haemophilia item bank based on International Classification of Functioning, Disability and Health: a systematic review

Hematology, 2023
Background and Objectives Haemophilia comprises a continuum of blood disorders that often include joint and muscular dysfunction, which may lead to a constellation of activity limitations and participation restrictions.
Bao-Feng Geng, Chun Feng, Shou-Guo Liu, Zhong-Li Jiang, Feng Lin   +4 more
doaj   +1 more source

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B

Haemophilia, 2010
Summary. Dogs with haemophilia A or haemophilia B exhibit spontaneous bleeding comparable with the spontaneous bleeding phenotype that occurs in humans with severe haemophilia. The phenotypic and genotypic characteristics of haemophilic dogs have been well‐described, and such dogs are suitable for testing prophylactic protein replacement therapy and ...
Elizabeth P. Merricks, Paris Margaritis, Dwight A. Bellinger, Valder R. Arruda, Katherine A. High, Katherine A. High, Mark A. Kay, Robin A. Raymer, Timothy C. Nichols, Helen W. G. Franck, Natalie DeFriess   +10 more
openaire   +4 more sources

Molecular pathology of haemophilia B. [PDF]

The EMBO Journal, 1989
Direct sequencing of amplified genomic DNA has been used to investigate the molecular basis of haemophilia B and thus identify specific amino acids that are essential for maintenance of structure or function of factor IX. Substitution of Cys 336, Asn 120 results in loss of circulating factor IX antigen and deletion of Arg 37 in gross reduction of ...
D R Bentley, P. M. Green, R S Mibashan, F Giannelli, Inga Marie Nilsson   +4 more
openaire   +3 more sources

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study

Orphanet Journal of Rare Diseases, 2022
Background Haemophilia bears substantial humanistic and economic burden on children and their caregivers. Characterising the differential impact of severe versus moderate paediatric haemophilia is important for clinical and health policy decisions.
Idaira Rodriguez-Santana, Pronabesh DasMahapatra, Tom Burke, Zalmai Hakimi, José Bartelt-Hofer, Jameel Nazir, Jamie O’Hara   +6 more
doaj   +1 more source

CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

Scientific Reports, 2017
Haemophilia B, a congenital haemorrhagic disease caused by mutations in coagulation factor IX gene (F9), is considered an appropriate target for genome editing technology.
Tsukasa Ohmori, Yasumitsu Nagao, Hiroaki Mizukami, Asuka Sakata, Shin-ichi Muramatsu, Keiya Ozawa, Shin-ichi Tominaga, Yutaka Hanazono, Satoshi Nishimura, Osamu Nureki, Yoichi Sakata   +10 more
doaj   +1 more source

Seroprevalence of Hepatitis B and Hepatitis C in People with Haemophilia at a Tertiary Care Centre, Assam, India: A Cross-sectional Study [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Prior to the advent of recombinant factor products, the treatment of haemophilia was mainly based on the administration of direct blood products like whole blood, Fresh Frozen Plasma (FFP), and cryoprecipitates. This led to a high incidence
Anupam Dutta, Luish Borboruah, Papori Gogoi   +2 more
doaj   +1 more source

The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study

Orphanet Journal of Rare Diseases, 2022
Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families.
Simon Fletcher, Kathryn Jenner, Luke Pembroke, Michael Holland, Kate Khair   +4 more
doaj   +1 more source

PERAWATAN GIGI DAN MULUT PENDERITA HEMOFILIA

Journal of Dentistry Indonesia, 2015
Haemophilia is a congenital haemorrhagic disorders passed down by the x linked recessive, divided into two: Haemophilia A caused by deficiency of factor VIII and Haemophilia B caused by deficiency of factor IX.
Siti Marhamah
doaj   +1 more source

Gene therapy in haemophilia: literature review and regional perspectives for Turkey

Therapeutic Advances in Hematology, 2022
Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by insufficient levels of factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) and characterized by spontaneous and trauma-related bleeding episodes.
Kaan Kavaklı, Bülent Antmen, Vahap Okan, Fahri Şahin, Selin Aytaç, Can Balkan, Ergül Berber, Zühre Kaya, Alphan Küpesiz, Bülent Zülfikar   +9 more
doaj   +1 more source